Table of Contents
Definition / general | Essential features | Terminology | ICD coding | Epidemiology | Sites | Pathophysiology | Etiology | Clinical features | Radiology description | Radiology images | Prognostic factors | Case reports | Treatment | Gross description | Gross images | Microscopic (histologic) description | Microscopic (histologic) images | Positive stains | Negative stains | Electron microscopy description | Electron microscopy images | Molecular / cytogenetics description | Molecular / cytogenetics images | Differential diagnosis | Board review style question #1 | Board review style answer #1 | Board review style question #2 | Board review style answer #2Cite this page: Obeidin F, Alexiev B. Synovial sarcoma. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/softtissuesynovialsarc.html. Accessed January 19th, 2021.
Definition / general
- Malignant soft tissue tumor of uncertain histogenesis with variable epithelial differentiation
Essential features
- Can occur in or around any tissue in the body
- Multiple morphologies, including monophasic spindle cell, biphasic, poorly differentiated, myxoid, ossifying and monophasic epithelial
- Monotonous spindle cells with vesicular, plump and overlapping nuclei with hemangiopericytic vessels
- TLE1+, Cytokeratin+, EMA+, BCL2+, CD99+
- Has a characteristic chromosomal translocation t(X;18)(p11;q11) involving genes SS18 and either SSX1, SSX2 or SSX4
Terminology
- Obsolete terms: malignant synovioma
ICD coding
- C49.9: Malignant neoplasm of connective and soft tissue, unspecified
Epidemiology
- Accounts for 5 - 10% of all soft tissue sarcomas
- Median age 35 years old, age range 0 to 85+
- Age range: 0 to 85+
- Slight male predominance (1.2:1)
- 17.6% of cases occur in children and young adults 0 - 19 years old (Pediatr Blood Cancer 2011;57:943)
Sites
- Can occur anywhere in the body
- Primary site distribution (Pediatr Blood Cancer 2011;57:943):
- Extremities: 68.7%
- Trunk: 15.7%
- Head and neck: 6.3%
- Intra-thoracic: 5.3%
- Intra-abdominal: 1.8%
- Other: 2.2%
Pathophysiology
- Driven by the chromosomal translocation t(X;18)(p11;q11) involving genes SS18 and either SSX1, SSX2 or SSX4
- Translocation has multiple effects on oncogenetic pathways, including the SWI/SNF chromatin remodeling complex, polycomb repressor complex and canonical Wnt pathway (Cancer Discov 2015;5:124)
- Translocation partner affects epithelial differentiation (Int J Clin Exp Pathol 2013;6:2272):
- SS18-SSX1: 60 - 70% monophasic, 30 - 40% biphasic
- SS18-SSX2: 97% monophasic, 3% biphasic
- SS18-SSX1 inhibits Snail gene while SS18-SSX2 inhibits Slug gene
- Interfering with Snail leads to stronger derepression of E-cadherin than does interfering with Slug
- Stronger E-cadherin and increased extracellular matrix protein MMP2 expression are needed for biphasic morphology to develop
Etiology
- Despite the name, the cells of origin are not synovial cells
- Histogenesis is still debated
- One study has shown stem cell marker expression suggesting that origin may be a multipotent mesenchymal stem cell (Stem Cells 2010;28:1119)
- One study using mice identified satellite cells (immature myoblasts) as a potential source (Cancer Cell 2007;11:375)
Clinical features
- Very rarely associated with prior radiation therapy (Mod Pathol 2002;15:998)
- Not classically known to be associated with any syndromes
Radiology description
- Most present as round to oval, lobulated masses
- Bone involvement is rare
- Ossifying synovial sarcomas have characteristic spotty radio-opacities caused by focal calcifications (Pathol Res Pract 2009;205:195)
Radiology images
Prognostic factors
- Poor prognostic factors:
- SS18-SSX1 translocation
- Monophasic and poorly differentiated subtypes (Cancer Med 2014;3:1404)
- Male gender (J Surg Oncol 2015;111:158)
- Older age at diagnosis (Br J Cancer 2015;113:1602)
- Size ≥ 5 cm (Cancer 2009;115:2988)
- Nonextremity location (Cancer 2009;115:2988)
- Deep seated tumors (Ann Surg Oncol 2013;20:73)
- Higher percentage of tumor necrosis (Am J Clin Oncol 2004;27:113)
- Mitotic activity ≥ 10/HPF or higher Ki67 activity (J Cancer Res Ther 2014;10:73)
- Tumor grade based on Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) (J Clin Oncol 2004;22:4040)
- Immunohistochemical expression of CXCR4 and IGF-1R (Orphanet J Rare Dis 2015;10:6)
- Positive surgical margins
- H3K27me3 and VEGF expression associated with histologic grade, distant metastasis and stage (Pathol Res Pract 2018;214:974)
- Grading:
- In adults: grade based on Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
- In children: new grading system by the Pediatric Oncology Group (POG) for nonrhabdomyosarcoma soft tissue sarcoma in children showed discrepant higher grading for synovial sarcoma compared to FNCLCC
Case reports
- 11 year old girl with left popliteal fossa mass arising from her tibial nerve (Rare Tumors 2018;10:2036361318776495)
- 17 year old boy with a retroperitoneal mass (JRSM Open 2018;9:2054270418760437)
- 31 year old woman with a left forearm nodule (Am J Dermatopathol 2018 May 8 [Epub ahead of print])
- 35 year old man with a mass on the left lateral border of the tongue (Ann R Coll Surg Engl 2018;100:e118)
- 37 year old woman with a large mediastinal mass (J Cancer Res Ther 2018;14:682)
Treatment
- Primarily surgical
- Radiotherapy and adjuvant chemotherapy have been evaluated in high risk situations (tumors > 5 cm or difficult to resect)
- Radiation therapy: adjuvant use has shown improvement in oncologic outcome and overall survival (J Surg Oncol 2015;111:158)
- Adjuvant chemotherapy:
- Data is conflicting on its use but can be considered in high risk patients
- Ifosfamide was shown to increase disease specific survival (Ann Surg 2007;246:105)
- Two large EORTC database clinical trials showed no benefit of doxorubicin on overall survival (Ann Oncol 2014;25:2425)
- Novel therapies:
- Initial PDL1 and CTLA4 studies have shown no benefit (Sarcoma 2013;2013:168145)
- Receptor tyrosine kinase inhibitor pazopanib has a promising trend toward better overall survival
- Tazemetostat, an EZH2 inhibitor, has also been studied in INI1 deficient tumors including synovial sarcoma (Curr Treat Options Oncol 2018;19:13)
- Early studies on T cell receptor based immunotherapy directed towards NY-ESO-1 in HLA-A*0201+ patients have demonstrated radiological and clinical benefit (J Clin Oncol 2011;29:917)
Gross description
- Varies depending on growth rate
- Slow growing tumors are well circumscribed, round or multilobular and have a smooth pseudocapsule
- Poorly differentiated and rapidly growing tumors are poorly circumscribed with a variegated appearance, often with necrosis or hemorrhage
Gross images
Microscopic (histologic) description
- General (Ann Diagn Pathol 2014;18:369):
- Two main subtypes: biphasic and monophasic spindle cell
- Rarer subtypes: poorly differentiated (round cell), monophasic epithelial, calcifying / ossifying and myxoid
- Biphasic:
- Architecture:
- Two components, spindle cells and gland-like epithelial structures
- Glandular lumina contain mucin
- Cytologic features:
- Epithelial component has moderate, distinct amphophilic cytoplasm with round to ovoid nuclei
- Rarely squamous metaplasia can occur
- Architecture:
- Monophasic:
- Architecture:
- Infiltrative borders
- Hypercellular fascicular architecture with little intervening stroma
- Can rarely show hyalinization or myxoid change
- Ill defined nuclear palisading may be seen
- Cytologic features:
- Monotonous cells with scant amphophilic cytoplasm, ovoid to spindled vesicular nuclei with evenly dispersed chromatin and inconspicuous nucleoli
- Nuclei often close enough to overlap with adjacent nuclei
- Architecture:
- Poorly differentiated: highly cellular round cells with hyperchromatic nuclei and frequent mitotic activity and necrosis
- Additional features:
- May have staghorn, branching ("hemangiopericytic") vessels
- Mast cells are common
- Focal calcification can be seen in 1/3 of cases
Microscopic (histologic) images
Contributed by Farres Obeidin, M.D.
Contributed by Debra Zynger, M.D.
Contributed by Mark R. Wick, M.D.
Positive stains
- TLE1: 80 - 90%, relatively specific and sensitive marker, but new studies are finding more tumors with TLE1 positivity (Am J Clin Pathol 2011;135:839, Mod Pathol 2009;22:872)
- Cytokeratins: ~90%, variable positivity depending on the keratin polypeptide and the component (Virchows Arch 2000;437:275)
- EMA: 29 - 90%, variable and focal, generally less than cytokeratins (Hum Pathol 1990;21:733, Am J Surg Pathol 2002;26:1434)
- BCL2: 79 - 100% (Cancer Genet Cytogenet 2009;193:1)
- Beta-catenin: 30 - 73%, (Oncogene 2014;33:5006)
- Calponin: at least focally positive in all tested cases (Histopathology 2003;42:588)
- CD99: 91%, CD56 100%, CD57 90%, calretinin 56 - 71%
- S100: 40% (Am J Clin Pathol 1999;112:641)
- NY-ESO-1: 76% strong and diffuse staining (Mod Pathol 2012;25:854)
- SYT: 87% , strong nuclear staining, may lack specificity (Mod Pathol 2007;20:522)
- ZO-1, claudin1 and occludin
- Glandular component of most biphasic cases were positive for ZO-1, claudin1 and occludin
- All monophasic synovial sarcomas were positive for ZO-1 yet only some were positive for claudin1 (29%) and occludin (21%) (Mod Pathol 2004;17:141)
Negative stains
- CD34, desmin, h-Caldesmon, myogenin, MyoD1, FLI1, WT1 (nuclear staining)
- SOX10: 93% negative (Mod Pathol 2014;27:55)
- INI1: 69% show reduced expression (Mod Pathol 2010;23:981)
- H3K27me3: 60% show loss
Electron microscopy description
- Glandular formation of epithelioid tumor cells with sparse luminal microvilli
Molecular / cytogenetics description
- t(X;18)(p11.2; q11): SYT-SSX1 fusion in 90%, can detect via RT-PCR
- Also t(X;18)(p11.21;q11): SYT-SSX2 fusion, variants can be detected by optimizing RT-PCR (Mod Pathol 2002;15:679, Hum Pathol 2001;32:105)
- p16INK4A gene deletion in 74% (Am J Clin Pathol 2006;126:866)
- High expression of EZH2 helps to distinguish poorly differentiated synovial sarcoma from monophasic and biphasic subtypes (J Transl Med 2012;10:216)
Molecular / cytogenetics images
Differential diagnosis
- Biphasic:
- Adenocarcinoma: lack spindle cell areas and are typically TLE1-
- Biphasic mesothelioma: can show sarcomatoid features and cytokeratin positivity, but WT1+ and lacks the SSX translocation
- Glandular nerve sheath tumors: very rarely malignant peripheral nerve sheath tumor and schwannoma can show glandular features
- Branchial anlage mixed tumor (ectopic hamartomatous thymoma ): composed of spindle cells and epithelial tissue, should also see mature adipose tissue, myoepithelial expression (CK5/6+, CK14+, SMA+, CD10+, calponin+) (Am J Surg Pathol 2004;28:1360)
- Monophasic:
- Malignant peripheral nerve sheath tumor (MPNST): hypo- and hypercellular areas; SOX10, molecular studies and clinical history are useful in making the diagnosis; often shows focal keratin positivity and TLE1+ in up to 30%; also can have loss of H3K27me3 in 34% of cases (Mod Pathol 2016;29:582)
- Cellular schwannoma: dilated vessels with hyalinized walls, S100 and SOX10 are diffusely positive, TLE1+ in most cases which can cause confusion
- Solitary fibrous tumor: CD34+ with a characteristic "patternless" pattern, STAT6+, TLE1 can be positive in up to 40%
- Leiomyosarcoma: often shows more nuclear pleomorphism with brighter eosinophilic cytoplasm; may be desmin+, SMA+, calponin+, h-Caldesmon+
- Spindle cell rhabdomyosarcoma: desmin+, myogenin+, myoD1+
- Adult fibrosarcoma: diagnosis of exclusion when other spindle cell sarcomas have been ruled out
- Dermatofibrosarcoma protuberans with fibrosarcomatous transformation: usually CD34+ and has an area with more classic histology
- Epithelioid sarcoma: can be keratin+, TLE1+ (30%) and have spindle cell morphology; CD34+ (50%) and INI1 lost in majority
- Biphenotypic sinonasal sarcoma: has neural and myogenic IHC markers, including S100 and SMA, calponin, desmin or myogenin; PAX3 rearrangements by FISH
- Sarcomatoid carcinoma: keratin+; look for overlying epithelium involved by carcinoma; TLE1- and lacks the SSX translocation
- Poorly differentiated
- Small round blue cell tumors
- SS18-SSX translocation studies and lineage specific markers such as myogenin, myoD1, desmin, FLI1 are useful
- Molecular studies for PAX3 / PAX7 rearrangements, EWSR rearrangements, CIC-DUX4 and BCOR rearrangements help rule out alveolar rhabdomyosarcoma, Ewing sarcoma and undifferentiated round cell sarcoma (previously Ewing-like sarcomas)
Board review style question #1
Board review style answer #1
E. Synovial sarcoma has fusion of SS18 with SSX1, SSX2 or SSX4. It typically occurs in younger patients, with the peak incidence in the third - fourth decade and most cases show at least focal cytokeratin expression. It is not associated with PAX3 rearrangements, a typical finding in alveolar rhabdomyosarcoma and biphenotypic sinonasal sarcoma. HHV8 is seen in Kaposi sarcoma.
Board review style question #2
- Which morphologic feature is commonly seen in synovial sarcoma?
- Chicken wire calcifications
- Extravasated red blood cells
- Hemangiopericytic vessels
- Nuclear pleomorphism
- Prominent storiform pattern
Board review style answer #2
C. Hemangiopericytic vessels and monotonous nuclei are commonly seen in synovial sarcoma. Chicken wire calcifications are typically seen with chondroblastoma. Extravasated red blood cells are common in nodular fasciitis, fibromatosis and Kaposi sarcoma. A storiform pattern is characteristic of dermatofibrosarcoma protuberans.
Comment Here
Comment Here